Research Exclusive Donation (RED)
LifeShare Oklahoma and Revalia Bio have forged a collaborative working relationship with a shared commitment to advancing biomedical research in the field of lung cancer, particularly for individuals in the end stage of malignancy. Revalia Bio, a biotech company specializing in biomedical research using human organs rather than animal models, has partnered with LifeShare to leverage the availability of organs from willing donors facing end-stage malignancy.
The primary focus of this collaboration is to address the pressing issue of lung cancer, which disproportionately affects Oklahomans. With Oklahoma ranking 42 out of 42 nationally for lung cancer survival at 21.2%, and 20% of individuals in the state receiving no follow-up care after a lung cancer diagnosis, there is a critical need for innovative approaches to research and treatment.
LifeShare and Revalia, in collaboration with local healthcare providers and hospitals, have established a program known as RED (Research, Education, and Donation) for end-stage malignancy patients. This program provides a unique option for individuals facing terminal illness to contribute to biomedical research using their organs. The collaboration ensures that donors understand their gift will not only maximize their legacy but also directly impact the future of cancer care.
By combining LifeShare's expertise in organ donation and transplantation with Revalia Bio's innovative approach to biomedical research, the partnership aims to improve understanding, treatment, and outcomes for lung cancer patients. The joint effort facilitates the collection of valuable data and human organ samples, enhancing the scientific community's ability to develop more effective therapies and interventions.
In summary, the collaboration between LifeShare of Oklahoma and Revalia Bio represents a pioneering effort to address the challenges of lung cancer in the state. Through the RED program, end-stage malignancy patients can make a significant contribution to biomedical research, fostering hope for advancements in cancer care and treatment that will benefit future generations.
The primary focus of this collaboration is to address the pressing issue of lung cancer, which disproportionately affects Oklahomans. With Oklahoma ranking 42 out of 42 nationally for lung cancer survival at 21.2%, and 20% of individuals in the state receiving no follow-up care after a lung cancer diagnosis, there is a critical need for innovative approaches to research and treatment.
LifeShare and Revalia, in collaboration with local healthcare providers and hospitals, have established a program known as RED (Research, Education, and Donation) for end-stage malignancy patients. This program provides a unique option for individuals facing terminal illness to contribute to biomedical research using their organs. The collaboration ensures that donors understand their gift will not only maximize their legacy but also directly impact the future of cancer care.
By combining LifeShare's expertise in organ donation and transplantation with Revalia Bio's innovative approach to biomedical research, the partnership aims to improve understanding, treatment, and outcomes for lung cancer patients. The joint effort facilitates the collection of valuable data and human organ samples, enhancing the scientific community's ability to develop more effective therapies and interventions.
In summary, the collaboration between LifeShare of Oklahoma and Revalia Bio represents a pioneering effort to address the challenges of lung cancer in the state. Through the RED program, end-stage malignancy patients can make a significant contribution to biomedical research, fostering hope for advancements in cancer care and treatment that will benefit future generations.